The Experts below are selected from a list of 2709 Experts worldwide ranked by ideXlab platform
Francois Goldwasser - One of the best experts on this subject based on the ideXlab platform.
-
Pneumatosis Intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
Investigational New Drugs, 2011Co-Authors: Romain Coriat, Stanislas Ropert, Bertrand Billemont, Stanislas Chaussade, P P Massault, Benoit Blanchet, O Vignaux, Francois GoldwasserAbstract:Recently, Pneumatosis Intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis Intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on Pneumatosis Intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to Pneumatosis Intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that Pneumatosis Intestinalis is a probable class-effect of anti-VEGF agents.
-
Pneumatosis Intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Investigational new drugs, 2010Co-Authors: Romain Coriat, Stanislas Ropert, Bertrand Billemont, Stanislas Chaussade, P P Massault, Benoit Blanchet, O Vignaux, Olivier Mir, Francois GoldwasserAbstract:Recently, Pneumatosis Intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis Intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on Pneumatosis Intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to Pneumatosis Intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that Pneumatosis Intestinalis is a probable class-effect of anti-VEGF agents.
Romain Coriat - One of the best experts on this subject based on the ideXlab platform.
-
Pneumatosis Intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
Investigational New Drugs, 2011Co-Authors: Romain Coriat, Stanislas Ropert, Bertrand Billemont, Stanislas Chaussade, P P Massault, Benoit Blanchet, O Vignaux, Francois GoldwasserAbstract:Recently, Pneumatosis Intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis Intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on Pneumatosis Intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to Pneumatosis Intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that Pneumatosis Intestinalis is a probable class-effect of anti-VEGF agents.
-
Pneumatosis Intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Investigational new drugs, 2010Co-Authors: Romain Coriat, Stanislas Ropert, Bertrand Billemont, Stanislas Chaussade, P P Massault, Benoit Blanchet, O Vignaux, Olivier Mir, Francois GoldwasserAbstract:Recently, Pneumatosis Intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis Intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on Pneumatosis Intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to Pneumatosis Intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that Pneumatosis Intestinalis is a probable class-effect of anti-VEGF agents.
P P Massault - One of the best experts on this subject based on the ideXlab platform.
-
Pneumatosis Intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
Investigational New Drugs, 2011Co-Authors: Romain Coriat, Stanislas Ropert, Bertrand Billemont, Stanislas Chaussade, P P Massault, Benoit Blanchet, O Vignaux, Francois GoldwasserAbstract:Recently, Pneumatosis Intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis Intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on Pneumatosis Intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to Pneumatosis Intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that Pneumatosis Intestinalis is a probable class-effect of anti-VEGF agents.
-
Pneumatosis Intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Investigational new drugs, 2010Co-Authors: Romain Coriat, Stanislas Ropert, Bertrand Billemont, Stanislas Chaussade, P P Massault, Benoit Blanchet, O Vignaux, Olivier Mir, Francois GoldwasserAbstract:Recently, Pneumatosis Intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis Intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on Pneumatosis Intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to Pneumatosis Intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that Pneumatosis Intestinalis is a probable class-effect of anti-VEGF agents.
Benoit Blanchet - One of the best experts on this subject based on the ideXlab platform.
-
Pneumatosis Intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
Investigational New Drugs, 2011Co-Authors: Romain Coriat, Stanislas Ropert, Bertrand Billemont, Stanislas Chaussade, P P Massault, Benoit Blanchet, O Vignaux, Francois GoldwasserAbstract:Recently, Pneumatosis Intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis Intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on Pneumatosis Intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to Pneumatosis Intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that Pneumatosis Intestinalis is a probable class-effect of anti-VEGF agents.
-
Pneumatosis Intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Investigational new drugs, 2010Co-Authors: Romain Coriat, Stanislas Ropert, Bertrand Billemont, Stanislas Chaussade, P P Massault, Benoit Blanchet, O Vignaux, Olivier Mir, Francois GoldwasserAbstract:Recently, Pneumatosis Intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis Intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on Pneumatosis Intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to Pneumatosis Intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that Pneumatosis Intestinalis is a probable class-effect of anti-VEGF agents.
Stanislas Chaussade - One of the best experts on this subject based on the ideXlab platform.
-
Pneumatosis Intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
Investigational New Drugs, 2011Co-Authors: Romain Coriat, Stanislas Ropert, Bertrand Billemont, Stanislas Chaussade, P P Massault, Benoit Blanchet, O Vignaux, Francois GoldwasserAbstract:Recently, Pneumatosis Intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis Intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on Pneumatosis Intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to Pneumatosis Intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that Pneumatosis Intestinalis is a probable class-effect of anti-VEGF agents.
-
Pneumatosis Intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Investigational new drugs, 2010Co-Authors: Romain Coriat, Stanislas Ropert, Bertrand Billemont, Stanislas Chaussade, P P Massault, Benoit Blanchet, O Vignaux, Olivier Mir, Francois GoldwasserAbstract:Recently, Pneumatosis Intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis Intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on Pneumatosis Intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to Pneumatosis Intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that Pneumatosis Intestinalis is a probable class-effect of anti-VEGF agents.